RxDoctor Payments Data

Michael Rosenthal, MD

Psychiatry · Dallas, TXNPI 1003800673

Payments from drug & device makers

$2,006in general payments, 2019–2025

Across 21 payments — averaging $95.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$696
  • Johnson & Johnson$354
  • Teva Pharmaceuticals USA, Inc.$327
  • AbbVie$242
  • Neurocrine Biosciences, Inc.$122
  • Takeda Pharmaceuticals U.S.A., Inc.$116
  • plus $148 from 3 others

What the payments were for

  • Food & beverage$1,88794%
  • Education$1186%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,006 in reported general payments places this provider in the 75th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$167,765
Medicare patients
180
Services billed
1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate28$83,621
AustedoDeutetrabenazine11$79,243
RexultiBrexpiprazole12$17,320
TrintellixVortioxetine Hydrobromide19$11,967
Aripiprazole86$7,677
Desvenlafaxine Succinate ErDesvenlafaxine Succinate131$4,761
Bupropion XlBupropion Hcl158$4,622
Duloxetine Hcl157$4,531
Venlafaxine Hcl ErVenlafaxine Hcl145$3,325
Memantine Hcl28$3,280
Methylphenidate Hcl115$3,142
Quetiapine Fumarate122$3,115
Lisdexamfetamine Dimesylate14$3,037
Olanzapine86$2,756
Alprazolam308$2,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$354$83,62128 claims
Teva Pharmaceuticals USA, Inc.Austedo$327$79,24311 claims
Otsuka America Pharmaceutical, Inc.Rexulti$696$17,32012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$116$11,96719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →